Who are Halfan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rukobia, Daklinza, Sirturo, Coartem, Invega Sustenna, Ketek.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/halofantrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Halfan — Competitive Intelligence Brief

Halfan (HALOFANTRINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Rare Disease.

marketed Antimalarial Potassium voltage-gated channel subfamily H member 2 Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Halfan (HALOFANTRINE) — GSK.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Halfan TARGET	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01
Rukobia	FOSTEMSAVIR	GSK	marketed		Potassium voltage-gated channel subfamily H member 2	2020-01-01
Daklinza	DACLATASVIR	Bristol-Myers Squibb	marketed	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	2015-01-01
Sirturo	bedaquiline	Janssen Therap	marketed	Diarylquinoline Antimycobacterial	Potassium voltage-gated channel subfamily H member 2	2012-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Invega Sustenna	PALIPERIDONE PALMITATE	Johnson & Johnson	marketed	Atypical Antipsychotic	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Ketek	TELITHROMYCIN	Sanofi	marketed	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

London School of Hygiene and Tropical Medicine · 6 drugs in this class
Sanofi · 3 drugs in this class
Epicentre · 2 drugs in this class
University of Oxford · 2 drugs in this class
· 2 drugs in this class
Frantz Viral Therapeutics, LLC · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Institut de Recherche pour le Developpement · 1 drug in this class
Centre de Recherche Médicale de Lambaréné · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Halfan — Competitive Intelligence Brief. https://druglandscape.com/ci/halofantrine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab